


Appendix 2 - Governance mapping

COVAX Facility Operationalisation and Vaccine Programme

Board Meeting, 29-30 September 2020



Description of bodies (1/5)

Oversight

Operations

Advisory

Allocation

Doc 03 - Appendix 2

Body

Role regarding the COVAX Facility

Gavi Board

- Responsible for overseeing the role of the Gavi Secretariat and the Alliance in the Facility and will have ultimate responsibility for decisions and effective implementation of the COVAX Facility. In this role it will:
 - Take responsibility to ensure that the Gavi Secretariat operates within the mandate granted to it;
 - Provide strategic direction and policy-making;
 - Receive regular reports from the Office of the COVAX Facility on operational progress and performance;
 - Receive updates from relevant Board Committees (e.g. AFC) on COVAX Facility matters; and
 - Provide strategic oversight of the COVID-19 programme and effective implementation including country engagement.

Audit and Finance Committee

- Responsible for:
 - ensuring funding availability for COVAX Facility operations, including review of the financial implications of Facility-related transactions;
 - ensuring the COVAX Facility is properly represented in Gavi's Annual Financial Report
 - and monitoring risk to Gavi, the Alliance, and the COVAX Facility.

Market-Sensitive Decisions Committee

- Responsible for reviewing business terms of proposed agreements with manufacturers to ensure: (i) reasonableness of terms and acceptable level of reputational risks; and (ii) availability of resources to back proposed agreements.

Description of bodies (2/5)

Oversight

Operations

Advisory

Allocation

Doc 03 - Appendix 2

Body

Role regarding the COVAX Facility

COVAX Facility Shareholders Council

- Provide strategic guidance and advice to the Office of the COVAX Facility (facilitated as appropriate through the Shareholders Council Executive Committee) on:
 - all non-technical elements of COVAX Facility strategy, policy and performance for all self-financing countries; and
 - issues relevant for management and oversight of activities, including tools necessary for monitoring progress and achievements.
- Receive regular updates from the Office of the COVAX Facility, including reports on allocation decisions and overall activities, and receive reports on all decisions or recommendations made by technical bodies (including the Market-Sensitive Decisions Committee, Independent Product Group, Procurement Reference Group and Independent Allocation Validation Group) and the Gavi Board.
- Receive regular updates from the Office of the COVAX Facility on expenditures, in particular spending of Participant down-payments/upfront payments.
- Share information with the COVAX Facility and other Shareholders.
- Select members to serve on the Executive Committee.
- Select members to serve on the Market-Sensitive Decisions Committee.
- Be open to all self-financing participants in the COVAX Facility, to whom allocation decisions and overall activities should be reported.

Description of bodies (3/5)

Oversight

Operations

Advisory

Allocation

Doc 03 - Appendix 2

Body

Role regarding the COVAX Facility

COVAX Facility Shareholders Council Executive Committee

- Convene between meetings of the Council.
- Receive regular reports from the Office of the COVAX Facility on technical decisions, operational progress and financial updates.
- Provide a clear link between the Council and other governance structures to ensure the consolidated advice/view of the Council is considered in relevant deliberations and that the Council is well prepared/briefed to provide advice as issues arise.
- Conduct more detailed discussions on forthcoming issues, help set agendas, draft papers, and ensure a longer-term view is taken in order to be an appropriate bridge between the Gavi Board and other bodies.
- Facilitate effective coordination with the Office of the COVAX Facility and other Facility stakeholders on the operation of the proposed COVAX Exchange.
- Identify emerging challenges within the Self-Financing Participants and seek to find consensus on these. Where consensus is not possible, request that the COVAX Consensus Group be convened.

AMC Engagement Group

- Will represent the AMC in the Governance of the Facility and include implementing economies donors and other parties engaged in the financing and operation of the AMC
- Will support real-time information exchange and providing strategic guidance and advice to the Office of the COVAX Facility on the operational aspects of the COVAX Facility.

AMC Stakeholders Group

- Discuss its investments in the AMC, options for additional financing, and receive specific reporting on progress achieved against the objectives of the AMC.

Description of bodies (4/5)

Oversight

Operations

Advisory

Allocation

Doc 03 - Appendix 2

Role regarding the COVAX Facility

COVAX Consensus Group

- Responsible to ensure that any disputes or challenges arising in the governance bodies of the Facility can be addressed swiftly and in the best interests of the aims of the Facility

Office of the COVAX Facility

- The Office will sit within the Gavi Secretariat as a dedicated team to support Facility operations
- It will comprise several new, dedicated teams: e.g. design and operations; deal making and vaccine portfolio management; country engagement; and finance.
- Establishment of Advance Purchase Agreements, and proposition of them to Market-Sensitive Decisions Committee for approval

Joint Allocation Taskforce

- Prepare a Vaccine Allocation Decision proposal for review and validation by the Independent Allocation Validation Group (IAVG). The proposal will be based on a data-driven allocation model
- Review all the data inputs needed for the allocation model, run the model, and verify its output.
- Respond to any requests for clarification from the IAVG, re-running the model if necessary.
- Provide administrative support to the IAVG, including convening the Group, keeping the membership updated, and ensuring transfer of relevant documentation.

Independent Allocation Validation Group

- Validates the Vaccine Allocation Decision proposal put forward by Joint Allocation Taskforce. Once validated, the VAD is passed to the Office of the COVAX Facility for implementation

Description of bodies (5/5)

Oversight

Operations

Advisory

Allocation

Doc 03 - Appendix 2

Role regarding the COVAX Facility

Independent Product Group

- Regularly review data and information relating to vaccine candidates (shared by the Secretariat and received from manufacturers, WHO, CEPI and the RDMIC)
- Provide guidance and independent technical advice to the Office of the COVAX Facility to inform the selection of candidates to be prioritised for deal making by the COVAX Facility, and eventually considered by the Market Sensitive Decisions Committee
- Regularly review the SARS-CoV-2 vaccine pipeline and the COVAX Facility portfolio on a rolling basis, taking into consideration updates related to clinical development, manufacturing and supply and provide advice on both the pipeline and COVAX Facility portfolio to the Office of the COVAX Facility and Board
- Engage with other bodies including, but not limited to, the CEPI RDMIC, PRG, SAGE Working Group etc.

Procurement Reference Group

- Responsible for providing independent advice to the Facility on its procurement strategy and key business terms of proposed advance purchase commitments with the manufacturers of these vaccine candidates.
- Provide guidance on ensuring an appropriately risk managed COVAX Portfolio taking into account the uncertainties related to current stages of vaccine development

Procurement coordinator

- Guidance on establishment of manufacturer supply agreements
- Monitoring of doses released from manufacturers and distributed to Participants against APCs
- Providing information on supply availability to Joint Allocation Taskforce